ARVN News and Press, Arvinas Inc. From 03/30/21

Arvinas (ARVN) shares are poised to rise significantly thanks to a "data-rich" second half of the year, according to Cantor analyst Alethia Young.She is reiterating her overweight rating and is raising her price target to $140 from $121.Based on yesterday's closing price of $58.19, that repre...

Oppenheimer is downgrading shares of Ascendis Pharma (ASND) from outperform to perform and removing its $212 price target.Analyst Leland Gershell says that Street estimates for sales of TransCon hGH (lonapegsomatropin) for pediatric growth hormone deficiency, a BLA for which was submitted las...

The following slide deck was published by Arvinas, Inc. in conjunction with this event. For further details see: Arvina (ARVN) Investor Presentation - Slideshow

With an estimated ~$530B war chest in total, large biopharma companies will continue to drive M&A activity in 2021, the analysts at Goldman Sachs predicted in a new analysis of the sector.Noting a ~110% YoY rise in deal volumes in February including ~221% YoY growth in U.S. mid-cap deals,...

Kymera Therapeutics is a next-generation targeted protein degradation company working to drug the undruggable genome. The company's platform has attracted three biopharma deals worth more than $3B. Kymera is filing three investigational drug applications in 2021 that might create ...

NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2020 an...

Illumina and its short reading technology pushed the sequencing costs down during the last decade. Long reads and artificial intelligence are improving the sequencing and will likely keep driving the costs lower. Several companies are building business models around these technolo...

Healthcare lagged the broader market last year, but that can change this year. A cyclical upturn as the pandemic abates and pent-up demand can boost healthcare. Best positioned are industry groups within healthcare that can achieve secular growth beyond the cyclical rise. Biot...

NEW HAVEN, Conn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D....

On January 13, ESSA announced a collaboration agreement with Janssen to evaluate ESSA's EPI-7386 in combo with Janssen's apalutamide and in combo with abiraterone acetate plus prednisone in patients with mCRPC. EPI-7386 is a novel approach to treat prostate cancer by targeting the N-t...